Right to cross-examination is not absolute and must be exercised diligently
The question whether cross examination is a discretionary remedy or a substantive right has come up before the Delhi High Court in context of post-grant oppositions filed against Novartis by three different Respondents with Controller General of Patents being pleaded as Respondent no 1, a) Indian Pharmaceutical Alliance (IPA) b) Micro Labs Limited and c)…